Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Penicillin Challenge for Allergy De-labeling in Pediatric ED
NCT05563610Phase 4Terminated
- Sponsor
- Phoenix Children's
- Start
- Sep 2022
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of amoxicillin in bacterial infection, otitis media, streptococcal pharyngitis and 2 more (2 arms), sponsored by Phoenix Children's. Primary endpoint: True Penicillin Allergies at 24 hours. Started Sep 2022; status: terminated.
02
Drugs
amoxicillin
03
Conditions
bacterial infectionotitis mediastreptococcal pharyngitispneumoniasinusitis
Beyond the preview
Go deeper on NCT05563610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05563610.